Pipe Line

Taskin Bio Regeneration

At Taskin Bioregeneration, our dedication to pioneering cell and gene therapies drives us to push the boundaries of medical science. Our pipeline showcases a range of innovative therapies, each aimed at addressing critical health conditions. Here’s a closer look at our current projects:

TasDes01: Graft Versus Host Disease (GVHD)

Status: Market Authorization
Therapy Type: Placenta Stromal Derived Cells
Overview: This therapy has reached the market authorization phase, offering advanced treatment solutions for GVHD using placenta-derived stromal cells.

TasDes02: Acute Respiratory Distress Syndrome (ARDS)

Status: Phase III
Therapy Type: Placenta Stromal Derived Cells
Overview: In the final stages of clinical trials, this therapy utilizes placenta-derived stromal cells to address the severe lung condition of ARDS.

TasDes03: Systemic Lupus Erythematosus (SLE)

Status: Phase II
Therapy Type: Placenta Stromal Derived Cells
Overview: Currently in Phase II, our therapy for SLE is exploring the potential of placenta-derived stromal cells to manage this complex autoimmune disorder.

TasDes04: Heart Failure (HF)

Status: Phase II
Therapy Type: Placenta Stromal Derived Cells
Overview: This therapy, in Phase II of clinical trials, focuses on using placenta-derived stromal cells to provide new hope for patients with heart failure.

TasWou01: Diabetic Foot (DF)

Status: Phase III
Therapy Type: Placenta Stromal Derived Cells
Overview: Our advanced therapy for diabetic foot, now in Phase III, aims to improve healing and mobility using placenta-derived stromal cells.

TasCar01: Multiple Myeloma (MM)

Status: Preclinical Study
Therapy Type: CAR T Cells
Overview: In the preclinical stage, this project focuses on developing CAR T cell therapies to target multiple myeloma, a challenging form of blood cancer.

TasTil01: Breast Cancer (BC)

Status: Phase II
Therapy Type: Tumor Infiltration Lymphocyte Based Therapy
Overview: This therapy, currently in Phase II, leverages tumor infiltration lymphocytes to offer a novel approach for treating breast cancer.

Our mission at Taskin Bioregeneration is to translate cutting-edge research into transformative therapies, enhancing patient outcomes and advancing the future of healthcare. Each project in our pipeline reflects our commitment to innovation and excellence in cell and gene therapy.

Product	Indication	Pipeline				Approval
		Discovery	Preclinical	Phase I/II	Phase III	Market Authorization
TasDes01	GVHD
TasDes02	ARDS
TasDes03	SLE
TasDes04	HF
TasWou01	DF
TasCar01	MM
TasTil01	BC

GVHD: Graft Versus Host Diseases
ARDS: Acute respiratory distress syndrome
SLE: Systemic lupus erythematosus
HF: Heart Failure
DF: Diabetic Foot
MM: Multiple Myeloma
BC: Breast Cancer